title: Targeted therapies in the treatment of advanced/metastatic NSCLC.
abstract: The treatment of advanced non-small cell lung cancer (NSCLC) has evolved substantially during the last years. Chemotherapy remains the cornerstone of treatment and prolongs survival with a positive impact on quality of life. However, we seem to have reached a plateau of activity in the treatment of NSCLC. Recently, the addition of bevacizumab or cetuximab to chemotherapy doublets has improved the outcome in selected patients with advanced NSCLC. Furthermore, the use of erlotinib and gefitinib is an alternative for second line treatment. Advances in our understanding of molecular biology of cancer and mechanisms of tumourigenesis have further enabled the discovery of several potential molecular targets and development of novel 'targeted therapies'. The purpose of this study is to review current data on the role of targeted therapies in the treatment of advanced NSCLC.
authors: EORTC Headquarters, EORTC-ETF, Avenue E.Mounierlaan, 83/11, Brussels B-1200, Belgium. athanasios.pallis@eortc.be
authors: A G
authors: AG
authors: Pallis
authors: L
authors: L
authors: Serfass
authors: R
authors: R
authors: Dziadziusko
authors: J P
authors: JP
authors: van Meerbeeck
authors: D
authors: D
authors: Fennell
authors: D
authors: D
authors: Lacombe
authors: J
authors: J
authors: Welch
authors: C
authors: C
authors: Gridelli
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000627:therapeutic use; D000068258:Bevacizumab; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D000068818:Cetuximab; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000188:drug therapy*; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D010880:Piperidines / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use; D011758:Pyrroles / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use; D000077157:Sorafenib; D000077210:Sunitinib; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D007211:Indoles; D010671:Phenylurea Compounds; D010880:Piperidines; D011725:Pyridines; D011758:Pyrroles; D011799:Quinazolines; D009536:Niacinamide; D000068258:Bevacizumab; D000077157:Sorafenib; D000069347:Erlotinib Hydrochloride; D000068818:Cetuximab; D000077156:Gefitinib; D000077210:Sunitinib; C452423:vandetanib